化疗引起的恶心和呕吐的治疗。
Treatment of chemotherapy-induced nausea and vomiting.
作者信息
Inrhaoun Hanane, Kullmann Tamás, Elghissassi Ibrahim, Mrabti Hind, Errihani Hassan
机构信息
Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
出版信息
J Gastrointest Cancer. 2012 Dec;43(4):541-6. doi: 10.1007/s12029-012-9401-6.
BACKGROUND
Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Since then, the prevention and treatment of chemotherapy-induced nausea and vomiting allows continuing efficacious chemotherapy that earlier had to be stopped sometimes for intolerance.
AIM
This anniversary review summarises the current antiemetic arsenal focussing on the most potent antiemetic drugs such as serotonin and substance P receptor antagonists.
RESULT
Antiemetic treatment improves quality of life under chemotherapy and contributes to the survival benefit as well. In spite of the use of these new drugs, a significant number of patients still experience nausea and vomiting. Special complications like delayed emesis can be alleviated by combination therapies.
CONCLUSION
Prevention and optimal management of chemotherapy-induced nausea and vomiting should be a goal for most patients receiving emetogenic chemotherapy.
背景
近期医学肿瘤学的进展包括抗癌治疗和支持治疗的发展。血清素受体拮抗剂于20年前引入临床实践。从那时起，化疗引起的恶心和呕吐的预防和治疗使得有效的化疗得以持续进行，而这种化疗在早期有时会因不耐受而不得不停止。
目的
本次周年综述总结了当前的止吐药物库，重点关注最有效的止吐药物，如血清素和P物质受体拮抗剂。
结果
止吐治疗可改善化疗期间的生活质量，并有助于提高生存率。尽管使用了这些新药，但仍有相当数量的患者会出现恶心和呕吐。联合治疗可缓解诸如延迟性呕吐等特殊并发症。
结论
对于大多数接受致吐性化疗的患者而言，预防和优化管理化疗引起的恶心和呕吐应成为目标。
Zotero 插件